Comparison of HLA-identical sibling bone marrow transplants (BMT) versus interferon plus cytarabine (IFN/Ara-C) for chronic myelogenous leukemia (CML) in chronic phase (CP).

被引：0
|
作者：
Guilhot, F
Sobocinski, K
Guilhot, J
Zhang, M
Giralt, S
Harousseau, JL
Michallet, M
Maloisel, F
Blaise, D
Guerci, A
Horowitz, M
机构：
[1] CHRU, France Intergrp LMC, Poitiers, France
[2] Med Coll Wisconsin, Int Bone Marrow Transplant Registry, Milwaukee, WI 53226 USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2343
引用
收藏
页码：545A / 545A
页数：1
相关论文
共 50 条
  • [1] Retrospective comparison of imatinib versus interferon plus cytarabine (IFN/Ara-c) for chronic myelogenous leukemia (CML) patients in chronic phase (CP).
    Guilhot, F
    Roy, L
    Guilhot, J
    Krahnke, T
    Guerci, A
    Druker, B
    Larson, R
    O'Brien, S
    So, C
    Massimini, G
    BLOOD, 2005, 106 (11) : 52A - 52A
  • [2] Effect of prior interferon therapy on outcome of HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia (CML) in first chronic phase.
    Horowitz, MM
    Giralt, S
    Szydlo, R
    Goldman, J
    VeumStone, J
    EXPERIMENTAL HEMATOLOGY, 1996, 24 (09) : 649 - 649
  • [3] Effect of prior interferon therapy on outcome of HLA-identical sibling bone marrow transplants for chronic myelogenous leukemia (CML) in first chronic phase.
    Horowitz, MM
    Giralt, S
    Szydlo, R
    Goldman, J
    VeumStone, J
    BLOOD, 1996, 88 (10) : 2716 - 2716
  • [4] THERAPY OF CHRONIC PHASE CML - COMPARISON OF HYDROXYUREA, INTERFERON AND HLA-IDENTICAL SIBLING TRANSPLANTS
    GALE, RP
    HEHLMANN, R
    HOROWITZ, MM
    ANSARI, H
    HOCHHAUS, A
    ZHANG, MJ
    BLOOD, 1994, 84 (10) : A538 - A538
  • [5] COMPARISON OF HLA-IDENTICAL SIBLING AND AUTOLOGOUS BONE-MARROW TRANSPLANTS FOR ACUTE MYELOGENOUS LEUKEMIA (AML)
    KEATING, A
    ROWLINGS, PA
    HOROWITZ, MM
    DICKE, K
    GALE, RP
    KLEIN, JP
    BLOOD, 1994, 84 (10) : A201 - A201
  • [6] Homoharringtonine (HHT) and low-dose cytarabine (ara-C) in patients with late chronic phase (CP) chronic myelogenous leukemia (CML).
    OBrien, S
    Kantarjian, H
    Keating, M
    Beran, M
    Rios, M
    Robinson, J
    Kornblau, S
    Talpaz, M
    BLOOD, 1997, 90 (10) : 2306 - 2306
  • [7] Imatinib (I) compared to I plus cytarabine (Ara-C) for the frontline treatment of chronic phase (CP) chronic myeloid leukemia (CML)
    Hurtado-Monroy, R.
    Vargas, P.
    Martinez, A.
    Cruz, J.
    Enriquez, V.
    Gutierrez, O.
    Candelaria, M.
    Aguayo, A.
    Cervera, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission
    Gale, RP
    Buchner, T
    Zhang, MJ
    Heinecke, A
    Champlin, RE
    Dicke, KA
    Gluckman, E
    Good, RA
    Gratwohl, A
    Herzig, RH
    Keating, A
    Klein, JP
    Marmont, AM
    Prentice, HG
    Rowlings, PA
    Sobocinski, KA
    Speck, B
    Weiner, RS
    Horowitz, MM
    LEUKEMIA, 1996, 10 (11) : 1687 - 1691
  • [9] Cost-effectiveness of imatinib versus interferon (IFN-α) plus low-dose cytarabine (ARA-C) for newly diagnosed chronic phase chronic myeloid leukemia (CML) in the the Netherlands
    Groot, MT
    Anstrom, KD
    Reed, SD
    Uyl-de Groot, CA
    VALUE IN HEALTH, 2004, 7 (06) : 644 - 644
  • [10] Induction of molecular remissions in chronic myelogenous leukemia (CML) with nonmyeloablative HLA-identical sibling allografts.
    Sandmaier, BM
    Niederwieser, D
    McSweeney, PA
    Shizuru, J
    Maloney, DG
    Radich, J
    Chauncey, T
    Deininger, M
    Blume, KG
    Storb, R
    BLOOD, 2000, 96 (11) : 201A - 201A
12345